Findings

What do systematic reviews say?

7 questions · 10 findings · 1 reviews · ENT

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 30%GRADE not reported 0 · 0%Very low 6 · 60%Low 1 · 10%Moderate 0 · 0%High 0 · 0%

Intranasal steroid spray vs placebo or no intervention

Presence of normal olfactory function · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection

It is very uncertain whether intranasal steroid spray changes presence of normal olfactory function Assessed by participants as a… compared with no intervention/placebo (very low certainty).

2 findings from 1 review

Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
RR 1.19 [0.85, 1.68]
1 study · 100 participants
Very low
Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
RR 2.31 [1.16, 4.64]
1 study · 77 participants
Very low

Intranasal steroid spray vs placebo or no intervention

Other adverse effects · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection

1 finding from 1 review

Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 77 participants
Very low

Intranasal steroid spray vs placebo or no intervention

Serious adverse events · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection

1 finding from 1 review

Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 77 participants
Very low

Intranasal steroid spray vs placebo or no intervention

Change in sense of smell · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection

3 findings from 1 review

Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 77 participants
Very low
Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 100 participants
Very low
Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 77 participants
Low

Intranasal steroid spray vs placebo or no intervention

Prevalence of parosmia · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intranasal steroid spray vs placebo or no intervention

Change in taste · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intranasal steroid spray vs placebo or no intervention

Disease‐related quality of life · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found